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ABSTRACT Cystinuria (OMIM 220100) is caused by the defective transport of cystine and the dibasic amino acids
in the proximal renal tubule and in the epithelial cells of the gastrointestinal tract. We analysed a cohort of 26
unrelated cystinuria patients diagnosed on the basis of stone formation. Direct sequencing of all coding regions and
exon-intron boundaries of the SLC3A1 and SLC7A9 genes allowed us to identify 26 different mutations in 23 out of
the 26 patients, in total they accounted for 40 affected chromosomes. Three of the 26 are novel mutations, two in
SLC3A1 and one in SLC7A9. Interestingly, two of our patients carried three mutations in SLC3A1 each, one patient
was mixed heterozygous for SLC3A1 and SLC7A9 mutations. In summary, these findings expand the spectrum of
SLC3A1 and SLC7A9 mutations and confirm the heterogeneity and complexity of cystinuria. If we assume an
autosomal recessive inheritance of the disease, our detection rate was 88.5% and thereby relatively high in comparison
to other studies. Nevertheless we have to consider that at least SLC7A9 mutations are often dominant, we therefore
think that our effective detection rate is higher. Additionally, the broad pathophysiological consequences of SLC7A9
mutations make an individual prognosis and genetic counselling difficult.
INTRODUCTION
Cystinuria (OMIM 220100) is an inherited
renal disease characterised by the defective
transport of cystine, lysine, ornithine and argi-
nine in the proximal tubule and in the epithelial
cells of the gastrointestinal tract. The resulting
urinary hyperexcretion of cystine leads to pre-
cipitation in the distal tubule and formation of
cystine stones. The prevalence ranges between
1 in 2,500 and 1 in 100,000 (for review: Palacin
et al. 2001). While cystinuria is rare in adults,
cystine stones represent 4-8% of renal stones in
children.
So far, two genes responsible for cystinuria
have been identified: SLC3A1 (chromosome
2p21) encodes the heavy subunit rBAT of the
renal b0,+ transporter while SLC7A9 (chromosome
19q12) encodes the light subunit b0,+AT (Fig. 1)
(Calonge et al. 1994; International Cystinuria
Consortium 1999).
Historically, the classification of cystinuria
was based on the urinary excretion pattern of
heterozygotes. Type I heterozygotes show a nor-
mal urinary excretion of all amino acids, in type
II and III heterozygotes an increased excretion of
cystine and the dibasic amino acids can be
observed (Rosenberg et al. 1964). After identi-
fication of the molecular basis of the disease a
new molecular classification was proposed: the
autosomal recessively inherited type I cystinuria
which is mainly caused by SLC3A1 mutations,
and the autosomal incomplete dominant non-
type I cystinuria associated with SLC7A9 mu-
tations (formerly types II and III). However, the
identification of single SLC3A1 mutations caus-
ing non-type I cystinuria and of recessive SLC7A9
mutations lead to a new strictly molecular clas-
sification (Dello Strogolo et al. 2002) which does
not include the biochemical phenotype: type A
cystinuria represents SLC3A1 mutations, and type
B cystinuria includes SLC7A9 mutations. Thus,
three genotypes can be delineated: AA, BB, and
in rare cases mixed cystinuria AB.
In addition to the classical cystinuria phe-
notype there are some reports on patients with
the hypotonia-cystinuria syndrome. In this
autosomal recessive disorder microdeletions of
the two contiguous genes SLC3A1 and PREPL
in 2p21 are not only associated with cystinuria
but also with neonatal hypotonia, failure to thrive
and growth retardation (for review: Martens et
al. 2007).
Here we report on our molecular findings in
26 cystinuria patients and the difficulties to
interpret the genetic data in respect to prognosis
and genetic counselling.
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Fig. 1. Schematic drawing of the physiological function of the rBAT and b0,+AT amino acid transport
system encoded by SLC3A1 and SLC7A9.
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Table 1: Results from molecular genetic testing in the cystinuria patient cohort
Patient Ethnic origin SLC3A1 mutations SLC7A9 mutations Cystinuria type
104 German G105R BB
IVS5+2T/C
156 German A382T BB
c.799_800insA
174 German F140S BB
F140S
368 German Q199X A?
644 Turkish A331V BB
A331V
780 German T216M AA
T216M
781 German ??
916 German R567fs AA
R567fs
Q224X
1004 German G105R BB
R333W
1166 German T216M AA
T216M
1283 German M467T G105R AB
1482 South East Europe R365L AA
T216M
c.1136+2/3delT
2487 German ??
2778 Dutch P508R AA
S547L
3029 Turkish N203fs B?
3858 German F599S AA
F599S
4057 German Y397C AA
R584X
4289 German M467T AA
D179Y
4611 German M467T AA
Q125X
5335 German G121E AA
G121E
5356 ??
6100 German R452W A?
6245 German M467T A?
6291 German S421fs B?
6389 German M123R AA
M467T
6670 German M467T A?
GENETICS OF CYSTINURIA
MATERIAL AND  METHODS
The 26 patients were referred for molecular
genetic testing because of (recurrent) kidney
stones by external hospitals and clinicians.
Patients´ genomic DNA was isolated from
peripheral blood samples by a simple salting-out
procedure. The whole coding region and the
intron/exon boundaries of SLC3A1 and SLC7A9
were amplified by PCR. Primer sequences and
PCR conditions have been described previously
(Botzenhart et al. 2002; Font-Llitjos et al. 2005).
In case of homozygosity of rare mutations large
deletions were excluded by DNA microarray
analysis using the 500K array system (Affymetrix,
High Wycombe, UK).
RESULTS  AND  DISCUSSION
By screening our cohort of 26 patients with
recurrent cystine kidney stones for mutations in
the SLC3A1 and the SLC7A9 genes we detected
mutations in 88.5% of cystinurics (Table 1). In
65.4%, both alleles of an individual were affected.
Homozygosity or compound heterozygosity for
SLC3A1 mutations was present in 11 cystinuria
patients, in another 5 cases two mutations were
detectable in the SLC7A9 gene. One patient was
mixed heterozygous with mutations in both
genes. In 6 probands, only one mutation in one
of the two genes was detectable. In 3 patients we
could not detect any mutation, neither in SLC3A1
nor in SLC7A9.
On the allelic level, the detection rate was
76.9%, SLC3A1 mutations accounted for 51.9%,
SLC7A9 mutations for 25%. The most common
SLC3A1 mutations were M467T and T216M in
SLC3A1, G105R was the most frequent mutation
in SLC7A9 (Table 2). These data confirm
observations from other studies that these three
mutations are indeed the most common ones
(Schmidt et al. 2004; Di Perna et al. 2008).
Interestingly, two of our patients carried three
mutations in the SLC3A1 gene (Table 1: patients
916 and 1482). The detection of three recessive
mutations in one gene is a rare finding but it has
also been known from other diseases like
autosomal recessive polycystic kidney diseases
(PKHD1 gene). The identification of three
mutations illustrates that two mutations can be
localised on the same allele, this might lead to
false-positive or false-negative results in carrier
diagnostics.
Gene Exon Mutation Frequencies (n)
SLC3A1 1 G121E 2
M123R 1
Q125X 1
D179Y 1
Q199X 1
3 T216M 5
Q224X 1
6/Intron 6 R365L 1
c.1136+2/3delT 1
7 Y397C 1
8 R452W 1
M467T 6
9 P508R 1
10 S547L 1
R567fs 2
R584X 1
F599S 2
SLC7A9 4 G105R 3
F140S 2
Intron 5 IVS5+2T/C 1
6 N203fs 1
c.799_800insA 1
10 A331V 2
R333W 1
11 A382T 1
12 S421fs 1
Table 2: Localisation and frequencies of the
mutations in the SLC3A1 and SLC7A9 genes in
our study cohort (new mutations are printed in
bold face)
Our detection rates correspond to that pub-
lished by other groups leaving 10-15% of alleles
unidentified. The failure to detect mutations in
single chromosomes might be explained by
putative dominance of some SLC7A9 alleles, in
these cases a second mutation is not needed to
affect the phenotype. Furthermore, it has been
suggested that genomic variants in the SLC7A9
gene might predispose a cystinuria phenotype
in case of a co-occurrence with other mutations
(Schmidt et al. 2003; Chatzikyriakidou et al.
2006). However, as our results and data from
other groups show a reliable diagnostic scree-
ning assay for cystinuria is accessible with a
detection rate of more than 85%.
In clinical practice, the molecular genetic
testing results might influence the prognosis and
therapy of cystinuria. While homozygosity or
compound heterozygosity for SLC3A1 mutations
are principally associated with an increased
cystine excretion, the age of kidney stone for-
mation is difficult to predict. Indeed, in sibs with
the same cystinuria genotype the age of onset
can differ remarkably. Nevertheless, all carriers
of two SLC3A1 or SLC7A9 mutations (geno-
types AA, BB, AB) will develop kidney stones
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in their live while the majority of SLC3A1
heterozygotes do not exhibit a biochemical phe-
notype. In contrast, the urinary excretion pattern
in heterozygote SLC7A9 mutation carriers is
extremely variable and does therefore hardly allow
a prediction of the clinical course, in particular in
childhood.
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